Three Pillars of Tuberculosis Treatment Development: A Review of Nanocarriers, Host-Directed Therapy, and Translational Pharmacology
Background: Barriers to Drug Delivery and Intracellular Survival
A review of tuberculosis treatment development examined nanocarrier-based drug delivery, host-directed therapy, and translational pharmacology together. It considers not only drugs targeting Mycobacterium tuberculosis, but also delivery to infection sites, modulation of host responses, and challenges in clinical development. This is distinct from a new experiment or clinical trial demonstrating the efficacy of a treatment combining all three strategies.
Tuberculosis treatment is burdened by long treatment courses, difficulties with adherence, and drug toxicity. Multidrug-resistant and extensively drug-resistant strains also complicate treatment. The authors identify the bacterium’s ability to survive inside host macrophages and the difficulty drugs face in penetrating granulomas as major barriers. This framing highlights the need to consider both antimicrobial activity and drug access to the interior of cells and to lesions.
The review also covers structural and molecular factors underlying drug resistance and persistent intracellular survival. However, the abstract provided does not report experimental findings on individual mechanisms or comparisons of drug-specific effects.
Key Findings: Review of Delivery Platforms and Host-Modulation Pathways
The drug-delivery approaches covered include polymeric nanoparticles, liposomes, solid lipid nanocarriers, dendrimers, biomimetic membrane-coated systems, and inhaled formulations. Receptor-mediated active targeting strategies are also reviewed. This list describes the technologies within the review’s scope; it does not establish the performance of any particular carrier. The abstract alone does not allow comparisons of platform-specific granuloma penetration depth, drug concentrations at target sites, or systemic toxicity.
Host-directed therapy seeks to modulate host responses. The review discusses autophagy, an intracellular degradation process; macrophage reprogramming; microRNA (miRNA) regulation; and antimicrobial peptide pathways. These approaches can be understood as development strategies that address the problem of intracellular bacterial survival from the host side. Reviewing these pathways, however, does not guarantee that every approach will enhance immunity or circumvent antibiotic resistance.
The review’s focus is to assess these delivery technologies and host-modulation strategies together from the perspective of clinical translation. The material provided offers no details on specific patient or comparator groups and no quantitative results supporting shorter treatment duration, higher cure rates, or fewer adverse effects. Accordingly, the abstract does not establish which platform or combination is more effective.
Implications and Outlook: A Development Framework That Includes Manufacturing and Regulatory Challenges
The authors review translational pharmacology, which connects research findings to clinical development, alongside manufacturing challenges and regulatory barriers. They thus move beyond identifying delivery systems or host-modulation targets to address problems encountered when developing them into therapies. The abstract does not report that a manufacturing process was optimized or that the feasibility of large-scale production was established.
Future directions also include artificial intelligence, CRISPR genomics, and messenger RNA–lipid nanoparticle (mRNA-LNP) vaccine platforms. Their specific performance and stage of clinical application cannot be confirmed from the available material, so these should be understood as development prospects.
The review’s contribution is to organize tuberculosis treatment development around linked challenges in drug delivery, host responses, and clinical translation. Assessing actual treatment outcomes requires further examination of the full review and its cited studies, including their study subjects, comparison conditions, endpoints, and results. The abstract currently available does not substantiate shorter treatment duration or changes to clinical guidelines.
Source: The paper’s bibliographic record and abstract in Europe PMC.
TB remains a significant global health burden due to protracted therapeutic courses, poor patient compliance, and toxicities associated with drug treatment, as well as concerns arising from increasingly prevalent multidrug-resistant and extensively drug-resistant strains of M. tuberculosis. The escalating prevalence of multidrug-resistant and extensively drug-resistant strains, compounded by the pathogen's extraordinary capacity to survive within host macrophages and pharmacologically impenetrable granulomas, has rendered conventional chemotherapy progressively insufficient, exposing an urgent and unmet need for transformative therapeutic innovation. This review comprehensively addresses that need by critically examining three converging paradigms redefining tuberculosis management: nanocarrier-based drug delivery systems, host-directed therapeutic strategies, and translational pharmacology. We systematically evaluate the structural and molecular determinants of Mycobacterium tuberculosis underpinning drug resistance and intracellular persistence, alongside an in-depth analysis of diverse nanocarrier platforms-polymeric nanoparticles, liposomes, solid lipid nanocarriers, dendrimers, biomimetic membrane-coated systems, and inhalable formulations, and host-directed approaches targeting autophagy, macrophage reprogramming, miRNA regulation, and antimicrobial peptide pathways. Receptor-mediated active targeting strategies, translational pharmacology frameworks, manufacturing challenges, and regulatory barriers are critically appraised, with an emerging roadmap encompassing artificial intelligence, CRISPR genomics, and mRNA-LNP vaccine platforms. This review equips researchers, clinicians, and pharmaceutical scientists with an integrated, evidence-based framework to accelerate the development and clinical translation of next-generation anti-tuberculosis therapeutics, ultimately contributing to the global ambition of ending tuberculosis.
For researchers developing tuberculosis treatment candidates, this review can serve as a starting point for organizing challenges in drug delivery, host-response modulation, and clinical translation. For example, a team evaluating a nanocarrier candidate could consider not only how its delivery strategy might connect with host-directed approaches, but also manufacturing challenges and regulatory barriers. The abstract, however, provides no candidate-specific performance data or patient treatment outcomes, so it is difficult to use as direct evidence for selecting a particular platform. Development decisions require follow-up examination of the full review and the conditions and comparative results in its cited studies. The material available can help frame development questions; it does not support changes to clinical prescribing or replacement of existing treatment.